Dendreon’s Provenge Prolongs Survival in Advanced Prostate Cancer

Dendreon has provided further support for its claim that its cancer vaccine Provenge significantly improved overall survival in men with advanced prostate cancer compared with those on a placebo in a Phase III study. Provenge (sipuleucel-T) extended median survival to 25.8 months compared with 21.7 months for placebo in the IMPACT (Immunotherapy for Prostate Adenocarcinoma Treatment) study. The vaccine also increased three-year survival 38 percent compared with a placebo, the company says.
Drug Industry Daily